Roemheld Syndrome Treatment in India and UAE | Complete Patient Guide

• ELIGIBLE PATIENTS:

• Adults with recurrent, unexplained palpitations, arrhythmias, or chest pain in whom primary cardiac disease has been ruled out by cardiology evaluation

• Patients with a confirmed or suspected hiatal hernia (Type I–IV) who experience cardiac symptoms temporally associated with meals, postprandial bloating, or positional changes

• Individuals with documented aerophagia, SIBO, gastroparesis, or IBS with coincident episodic arrhythmias (PACs, PVCs, SVT, or AF)

• Patients with persistent symptoms despite empirical proton-pump inhibitor (PPI) or antacid therapy who have not received a formal Roemheld Syndrome evaluation

• Patients previously subjected to extensive negative cardiac workup (normal coronary angiography, normal stress echocardiography) seeking a diagnostic explanation

• Pediatric cases (adolescents) with aerophagia-driven episodes may also be candidates for conservative management

• REQUIRED DIAGNOSTIC WORKUP (PRE-TREATMENT):

• 12-lead ECG and 24–48-hour Holter monitor (to document arrhythmia type and correlate with GI symptom diary)

• 2D Echocardiography (ECHO) with Doppler — to rule out structural cardiac disease and assess pericardial effusion from chronic compression

• Upper GI Endoscopy (OGD/EGD) — to identify hiatal hernia grade, esophagitis, or gastric pathology

• Barium swallow / Upper GI Series — for dynamic assessment of hiatal hernia size and type

• CT Thorax-Abdomen (with contrast, if indicated) — to assess intrathoracic stomach volume and para-esophageal hernia anatomy for surgical planning

• Gastric emptying scintigraphy (nuclear medicine study) — if gastroparesis is suspected as the primary driver

• Hydrogen/Methane Breath Testing — for SIBO and carbohydrate malabsorption assessment

• High-resolution esophageal manometry + 24-hour ambulatory pH-impedance monitoring — mandatory prior to any anti-reflux surgical intervention

• Autonomic function testing (tilt-table, heart rate variability analysis) — in cases with prominent vasovagal or dysautonomic features

• Blood panel: Complete blood count, thyroid function (TSH/fT4), serum electrolytes, magnesium, and fasting glucose — to exclude metabolic contributors to arrhythmia

• CONTRAINDICATIONS / RELATIVE CONTRAINDICATIONS:

• Active primary cardiac arrhythmia (e.g., confirmed AF with structural heart disease, WPW syndrome) requiring independent cardiac management before GI intervention

• Severe, uncontrolled coagulopathy or anticoagulation dependency (relative contraindication for endoscopic or surgical approaches)

• Advanced liver cirrhosis with portal hypertension (increases surgical risk for hiatal repair)

• Patient unwilling or unable to comply with post-operative dietary and lifestyle modifications (predictive of symptom recurrence after surgical repair)

• BMI >50 without prior bariatric assessment (staged approach recommended in super-obese patients)

• Pregnancy (surgical interventions deferred; conservative management only)

Treatment for Roemheld Syndrome is individualized based on the identified primary GI driver, arrhythmia burden, and anatomical findings. A stepwise escalation model is employed by GAF Healthcare's partner MDT teams.

STEP 1 — DIETARY, BEHAVIORAL & LIFESTYLE MODIFICATION (All patients; first-line):

Elimination of gas-producing foods (FODMAPs, carbonated beverages, cruciferous vegetables), eating smaller and more frequent meals, avoidance of reclining within 3 hours of meals, weight optimization, and diaphragmatic breathing retraining. Behavioral therapy for aerophagia (a recognized trigger) includes speech therapy techniques and biofeedback. These measures alone resolve symptoms in approximately 20–30% of mild cases.

STEP 2 — PHARMACOLOGICAL MANAGEMENT (Moderate cases):

• Proton Pump Inhibitors (PPIs): Pantoprazole, Rabeprazole, or Esomeprazole (40 mg once or twice daily) to reduce acid-mediated gastroparesis and gastroesophageal reflux-driven vagal stimulation.

• Prokinetic Agents: Domperidone (10 mg TID), Metoclopramide, or Prucalopride — to accelerate gastric emptying and reduce distension in gastroparesis-driven cases.

• Simethicone / Activated Charcoal: For symptomatic gas relief, reducing intragastric gas volume acutely.

• SIBO-targeted Antibiotic Therapy: Rifaximin (550 mg TID × 14 days) — the preferred non-absorbable antibiotic for SIBO eradication, with documented reduction in bloating-associated arrhythmic episodes.

• Low-dose Beta-Blockers (e.g., Metoprolol Succinate 25–50 mg): Used adjunctively to blunt the cardioinhibitory vagal response while GI therapy is established; not a standalone solution.

• Vagolytic agents (low-dose Hyoscine Butylbromide): In selected patients with dominant vagal parasympathetic drive.

STEP 3 — ENDOSCOPIC INTERVENTIONS (Refractory cases without large anatomical hernia):

• Transoral Incisionless Fundoplication (TIF 2.0): A flexible endoscopic platform that recreates the gastroesophageal valve without incisions, reducing hiatal hernia grade and reflux-mediated vagal stimulation. Performed under general anesthesia, no external incisions.

• Endoscopic Hiatal Hernia Reduction (experimental/advanced centers): Direct endoscopic manipulation to reduce small sliding hernias combined with endoscopic suturing systems (e.g., Overstitch, Apollo Endosurgery).

• Per-Oral Endoscopic Myotomy (G-POEM / POP): For concurrent gastroparesis as the primary driver — a submucosal endoscopic tunnel technique that performs pyloromyotomy to accelerate gastric emptying, directly reducing gastric volume and compression.

STEP 4 — LAPAROSCOPIC & ROBOTIC SURGICAL REPAIR (Definitive treatment for large hiatal hernia / Type II–IV para-esophageal hernia):

• Laparoscopic Nissen Fundoplication (360°): The gold-standard anti-reflux procedure for Type I sliding hiatal hernia with Roemheld Syndrome. Performed through 4–5 port laparoscopy; the gastric fundus is wrapped 360° around the lower esophagus, re-establishing the high-pressure zone and correcting the angle of His.

• Laparoscopic Toupet Fundoplication (270° posterior wrap): Preferred in patients with documented esophageal dysmotility on manometry, reducing the risk of post-operative dysphagia.

• Laparoscopic Para-Esophageal Hernia Repair with Mesh Cruroplasty: For large Type III/IV hernias, the intrathoracic stomach is reduced, the hernia sac excised, and the diaphragmatic crura are reinforced with lightweight biologic or biosynthetic mesh (e.g., Permacol, Gore Bio-A) to prevent recurrence. This directly eliminates the cardiac compression mechanism.

• Robotic-Assisted Hiatal Hernia Repair (da Vinci Xi/SP System): Available at premium partner hospitals in India (Medanta, Apollo, Fortis) and the UAE (Cleveland Clinic Abu Dhabi, Mediclinic City Hospital). Robotic platforms offer superior 3D visualization in the narrow mediastinal space, articulated wristed instrumentation for precise crural suturing, and measurably reduced conversion rates versus standard laparoscopy — particularly advantageous in revisional cases and BMI >35.

• Gastropexy (Laparoscopic Gastric Fixation): In high-surgical-risk patients unfit for full fundoplication, the stomach is anchored to the anterior abdominal wall to prevent recurrent herniation and distension-mediated cardiac compression.

CARDIOLOGY CO-MANAGEMENT:

For patients with persistent arrhythmias during the treatment phase, electrophysiology consultation is integrated. Catheter ablation (radiofrequency or cryoablation) may be offered concurrently if a discrete arrhythmia focus is identified — though in true Roemheld Syndrome, arrhythmia resolution typically follows successful GI treatment without requiring ablation.

PRE-ARRIVAL (2–4 weeks before travel):

• GAF Healthcare coordinator collects medical records, prior ECGs, endoscopy reports, and imaging for remote MDT review.

• Indian e-Medical Visa or UAE entry visa facilitated by GAF Healthcare's dedicated visa assistance team.

• Tailored treatment plan and cost estimate issued in writing; pre-travel dietary guidelines for GI preparation dispatched to the patient.

DAY 1 — ARRIVAL & INITIAL ASSESSMENT:

• Airport pickup by GAF Healthcare's ground team; transfer to hospital or partner accommodation.

• Admission to hospital; consultation with gastroenterologist and cardiologist on the same day.

• Baseline blood work, ECG, and clinical examination completed.

DAY 2–4 — DIAGNOSTIC WORKUP PHASE:

• Upper GI endoscopy performed (Day 2, outpatient or day-care basis under moderate sedation).

• 24–48-hour Holter monitoring initiated simultaneously with GI symptom diary.

• High-resolution manometry and pH-impedance study conducted (if surgical pathway is anticipated).

• CT thorax-abdomen reviewed by radiologist and surgical team.

• MDT case conference: Gastroenterologist, Upper GI Surgeon, Cardiologist, and Electrophysiologist (if indicated) formalize treatment plan.

DAY 5 — PRE-PROCEDURE PREPARATION (if proceeding to endoscopic or surgical intervention):

• Anesthesia assessment and cardiac clearance for procedure.

• Nil-by-mouth protocol initiated; pre-operative antibiotic prophylaxis administered.

• Informed consent process completed with GAF Healthcare's interpreter if required.

DAY 6 — PROCEDURE DAY:

• Conservative/pharmacological pathway: Formal medication regimen initiated; dietitian review; no anesthesia required. Patient may remain in hospital for observation or managed as outpatient.

• Endoscopic pathway (TIF 2.0 / G-POEM): 60–120-minute procedure under general anesthesia; recovery room observation for 4–6 hours; admission for 1 night for monitoring.

• Laparoscopic/Robotic Nissen or Para-Esophageal Repair: 90–180-minute procedure under general anesthesia; ICU or high-dependency observation for 12–24 hours post-operatively.

DAY 7–9 — IMMEDIATE POST-OPERATIVE RECOVERY (Surgical/Endoscopic patients):

• Clear liquid diet advanced to semi-solid diet by Day 7–8 under dietitian supervision.

• Pain management with multimodal analgesia (IV paracetamol, ketorolac, low-dose opioid PRN).

• DVT prophylaxis: Low-molecular-weight heparin (LMWH) and compression stockings.

• 12-lead ECG and 24-hour cardiac monitoring continued; arrhythmia frequency documented and compared to baseline Holter.

• Chest X-ray performed to confirm diaphragmatic position and exclude pneumothorax.

• Physiotherapy: Early ambulation Day 1 post-op; diaphragmatic breathing exercises initiated.

DAY 10–14 — HOSPITAL DISCHARGE & IN-COUNTRY RECOVERY:

• Discharge once tolerating semi-solid diet, pain controlled on oral analgesia, and no new arrhythmic episodes.

• Transfer to GAF Healthcare's partner serviced apartment or hotel for recuperation.

• Outpatient follow-up with surgical/gastroenterology team at Day 10–12 post-procedure for wound check and symptom review.

• Holter monitor re-applied for 24 hours at Day 10–14 to document arrhythmia response to treatment.

• Dietitian telehealth session; soft diet guidelines for the next 6 weeks issued.

FIT-TO-FLY MILESTONE:

• Pharmacological management only: Fit to fly in 3–5 days after diagnostic workup and medication initiation (1–2 weeks total stay).

• Post-endoscopic (TIF 2.0 / G-POEM): Fit to fly approximately 10–14 days post-procedure.

• Post-laparoscopic/robotic surgery: Fit to fly 14–21 days post-operatively, subject to surgeon clearance, confirmed absence of pneumothorax, and stable cardiac rhythm. Long-haul flights recommended only after 21 days.

LONG-TERM RECOVERY (At Home, 6–12 weeks):

• Strict graded dietary progression: liquid → semi-solid → soft → normal over 6 weeks.

• Avoidance of heavy lifting (>5 kg) or strenuous exercise for 4–6 weeks post-surgery.

• Continue prescribed PPI therapy for minimum 8–12 weeks post-operatively.

• Remote follow-up teleconsultations with GAF Healthcare's partner team at 4 weeks, 3 months, and 6 months.

• Repeat Holter monitor at 3 months to confirm sustained arrhythmia resolution.

• Full return to normal activity and diet expected by 8–12 weeks post-surgery.